rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-267-270rsp-3174Research ArticleПРОБЛЕМЫ РЕВМАТОЛОГИИ В ПЕРИОД ПАНДЕМИИ КОРОНОВИРУСНОЙ БОЛЕЗНИ 2019PROBLEMS OF RHEUMATOLOGY DURING THE 2019 CORONAVIRUS PANDEMICОсобенности течения и исходов COVID-19 у больных аксиальным спондилоартритомFeatures of the course and outcomes of COVID-19 in patients with axial spondyloarthritisЭрдесШ. Ф.ErdesSh. F.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

123456_57@mail.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202209072022603267270Copyright © Эрдес Ш.Ф., 20222022Эрдес Ш.Ф.Erdes S.F.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3174

Пандемия коронавирусной болезни 2019 года (COVID-19, coronavirus disease 2019) является особенно сложной не только для врачей, но и для пациентов с воспалительными заболеваниями, включая спондилоартриты. За последние два года проведено большое число исследований, посвященных изучению влияния COVID-19 на пациентов с ревматическими заболеваниями, однако выводы из них не всегда однозначны. Учитывая растущее число случаев заражения COVID-19 во всем мире, существует необходимость оценки влияния отдельных заболеваний на его исходы. Результаты изучения COVID-19 при спондилоартритах ограничиваются единичными сообщениями о случаях заболевания. Более того, литература, посвященная исходам COVID-19 исключительно у пациентов с аксиальным спондилоартритом, до недавнего времени практически отсутствовала. Однако за последние несколько месяцев опубликовано два больших исследования, в общей сложности проанализировавших исходы заражения инфекцией SARS-CoV-2 более 14000 больных спондилоартритами. В статье обсуждаются результаты этих исследований, авторы которых пришли к выводу, что аксиальный спондилоартрит и проводимая при этом заболевании терапия не повышают риск заражения и не утяжеляют исходы COVID-19. 

The 2019 coronavirus disease pandemic (COVID-19) is particularly challenging not only for doctors, but also for patients with inflammatory diseases, including spondyloarthritis. Although a large number of studies have been conducted over the past 2 years on the effect of COVID-19 on patients with rheumatic diseases, however, the conclusions from them are not always unambiguous. Given the growing number of cases of COVID-19 infection worldwide, there is a need to study the impact of individual diseases on its outcomes. The results of the study of COVID-19 in spondyloarthritis are limited to isolated reports of cases of the disease. Moreover, there is practically no literature devoted to the outcomes of COVID-19 exclusively in patients with axial spondyloarthritis. However, over the past few months, two large studies have been publishe d, in total, analyzing the outcomes of infection with SARS-CoV-2 in more than 14,000 patients with spondyloarthritis. The article discusses the results of these studies, the result of which is the conclusion that the presented data should convince both patients and doctors that axial spondyloarthritis and the therapy carried out for its treatment does not increase the risk of infection and does not aggravate the outcomes of COVID-19. 

COVID-19аксиальный спондилоартритисходыCOVID-19axial spondyloarthritisoutcomesСтатья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В. . Насоновой», № государственного задания 1021051503111-9.ReferencesSchreiber K, Hendricks O. First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea. Lancet Rheumatol. 2021;3(10):e673-e675. doi: 10.1016/ S2665-9913(21)00213-7Schreiber K, Hendricks O. First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea. Lancet Rheumatol. 2021;3(10):e673-e675. doi: 10.1016/ S2665-9913(21)00213-7Wang F, Ma Y, Xu S, Liu H, Chen Y, Yang H, et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis. Clin Rheumatol. 2022;41(7):2213-2223. doi: 10.1007/s10067-022-06087-1Wang F, Ma Y, Xu S, Liu H, Chen Y, Yang H, et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis. Clin Rheumatol. 2022;41(7):2213-2223. doi: 10.1007/s10067-022-06087-1Насонов ЕЛ, Белов БС, Лила АМ, Аронова ЕС, Гриднева ГИ, Кудрявцева АВ, и др. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научно-практическая ревматология. 2021;59(6):666-675. doi: 10.47360/1995-4484-2021-666-675Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(6):666-675 (In Russ.). doi: 10.47360/1995-4484-2021-666-675Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Jorge A, D’Silva KM, Cohen A, Wallace ZS, McCormick N, Zhang Y, et al. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: A cohort study. Lancet Rheu matol. 2021;3(2):e131-e137. doi: 10.1016/S2665-9913(20)30422-7Jorge A, D’Silva KM, Cohen A, Wallace ZS, McCormick N, Zhang Y, et al. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: A cohort study. Lancet Rheu matol. 2021;3(2):e131-e137. doi: 10.1016/S2665-9913(20)30422-7D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases – A nationwide cohort study. J Autoimmun. 2021;125:102739. doi: 10.1016/j.jaut.2021.102739Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases – A nationwide cohort study. J Autoimmun. 2021;125:102739. doi: 10.1016/j.jaut.2021.102739El Hasbani G, Jawad A, Uthman I. Axial and peripheral spondyloarthritis triggered by SARS-CoV-2 infection: A report of two cases. Reumatismo. 2021;73(1):59-63. doi: 10.4081/reumatismo.2021.1374El Hasbani G, Jawad A, Uthman I. Axial and peripheral spondyloarthritis triggered by SARS-CoV-2 infection: A report of two cases. Reumatismo. 2021;73(1):59-63. doi: 10.4081/reumatismo.2021.1374Saikali W, Gharib S. The first non-radiographic axial spondyloarthrits with COVID-19. Immun Inflamm Dis. 2021;9(3):628-631. doi: 10.1002/iid3.448Saikali W, Gharib S. The first non-radiographic axial spondyloarthrits with COVID-19. Immun Inflamm Dis. 2021;9(3):628-631. doi: 10.1002/iid3.448Румянцева ДГ, Урумова ММ, Эрдес ШФ. Новая коронавирусная инфекция COVID-19 как триггер развития симптомов анкилозирующего спондилита. Клиническое наблюдение. Терапевтический архив. 2021;93(5):609-612. doi: 10.26442/00403660.2021.05.200793Rumiantceva DG, Urumova MM, Erdes SF. New coronavirus infection COVID-19 as a trigger for the development of symptoms of ankylosing spondylitis. Case report. Terapevticheskii arkhiv. 2021;93(5):609- 612 (In Russ.). doi: 10.26442/00403660.2021.05.200793Rosenbaum JT, Hamilton H, Choi D, Weisman MH, Reveille JD, Winthrop KL. Biologics, spondylitis and COVID-19. Ann Rheum Dis. 2020;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941Rosenbaum JT, Hamilton H, Choi D, Weisman MH, Reveille JD, Winthrop KL. Biologics, spondylitis and COVID-19. Ann Rheum Dis. 2020;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941Rosenbaum JT, Weisman MH, Hamilton H, Shafer C, Aslanyan E, Howard RA, et al. The interplay between COVID-19 and spondyloarthritis or its treatment. J Rheumatol. 2022;49(2): 225-229. doi: 10.3899/jrheum.210742Rosenbaum JT, Weisman MH, Hamilton H, Shafer C, Aslanyan E, Howard RA, et al. The interplay between COVID-19 and spondyloarthritis or its treatment. J Rheumatol. 2022;49(2): 225-229. doi: 10.3899/jrheum.210742Raiker R, Pakhchanian H, Kavadichanda C, Gupta L, Kardeş S, Ahmed S. Axial spondyloarthritis may protect against poor outcomes in COVID-19: Propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. Clin Rheumatol. 2022;41(3):721-730. doi: 10.1007/s10067-021-05979-yRaiker R, Pakhchanian H, Kavadichanda C, Gupta L, Kardeş S, Ahmed S. Axial spondyloarthritis may protect against poor outcomes in COVID-19: Propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. Clin Rheumatol. 2022;41(3):721-730. doi: 10.1007/s10067-021-05979-yStrangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Baslılar S, Pehlivan O. Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents. Rev Assoc Med Bras (1992). 2021;67(9):1286-1292. doi: 10.1590/1806-9282.20210568Baslılar S, Pehlivan O. Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents. Rev Assoc Med Bras (1992). 2021;67(9):1286-1292. doi: 10.1590/1806-9282.20210568Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al.; OpenSAFELY Collaborative. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: An OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943-951. doi: 10.1136/annrheumdis-2020-219517Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al.; OpenSAFELY Collaborative. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: An OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943-951. doi: 10.1136/annrheumdis-2020-219517

The authors declare that there are no conflicts of interest present.